Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) EBT Margin (2018 - 2025)

Historic EBT Margin for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to 9.15%.

  • 10x Genomics' EBT Margin rose 201700.0% to 9.15% in Q4 2025 from the same period last year, while for Dec 2025 it was 6.21%, marking a year-over-year increase of 228900.0%. This contributed to the annual value of 6.21% for FY2025, which is 228900.0% up from last year.
  • As of Q4 2025, 10x Genomics' EBT Margin stood at 9.15%, which was up 201700.0% from 18.93% recorded in Q3 2025.
  • Over the past 5 years, 10x Genomics' EBT Margin peaked at 21.4% during Q2 2025, and registered a low of 59.71% during Q3 2023.
  • Over the past 5 years, 10x Genomics' median EBT Margin value was 23.46% (recorded in 2024), while the average stood at 24.28%.
  • Its EBT Margin has fluctuated over the past 5 years, first soared by 3529900bps in 2021, then crashed by -471000bps in 2022.
  • Quarter analysis of 5 years shows 10x Genomics' EBT Margin stood at 11.14% in 2021, then grew by 6bps to 10.5% in 2022, then tumbled by -141bps to 25.33% in 2023, then decreased by -16bps to 29.32% in 2024, then skyrocketed by 69bps to 9.15% in 2025.
  • Its EBT Margin stands at 9.15% for Q4 2025, versus 18.93% for Q3 2025 and 21.4% for Q2 2025.